Study design and population
This was a In the ESAX-DN study, patients were randomized to either esaxerenone or placebo treatment for 52 weeks after a 4-week run-in period, continuing their treatment with RAS inhibitors at a constant dosage throughout the study. To minimize the risk of increasing serum potassium (K